

Product Information

Product ID G1209

CAS No. 1032754-93-0

Chemical Name

Synonym RG7422, Apitolisib, GNE 390

Formula C₂₃H₃₀N₈O₃S

Formula Wt. 498.60

Melting Point


Purity $\geq 98\%$

Solubility	DMSO	20 mg/mL (40.11 mM)
	Water	Insoluble
	Ethanol	Insoluble

Store Temp 4°C

Ship Temp Ambient

Description GDC-0980 is an inhibitor of PI3K and mTORC1/2 that exhibits anticancer chemotherapeutic and anti-angiogenic activities. GDC-0980 inhibits cell growth in uterine serous carcinoma cells and decreases vascular density by altering vascular permeability parameter K (trans) in other cellular models. GDC-0980 inhibits cell growth and tumor growth across many cancer cell lines and models, including breast cancer, prostate cancer, and lung cancer.



Pricing and Availability

Bulk quantities available upon request

Product ID	Size	List Price
G1209	1 mg	\$112.80
G1209	5 mg	\$191.10
G1209	10 mg	\$338.40

References English DP, Bellone S, Cocco E, et al. Oncogenic PIK3CA gene mutations and HER2/neu gene amplifications determine the sensitivity of uterine serous carcinoma cell lines to GDC-0980, a selective inhibitor of Class I PI3 kinase and mTOR kinase (TORC1/2). *Am J Obstet Gynecol.* 2013 Nov;209(5):465.e1-9. PMID: 23891627.

Sampath D, Oeh J, Wyatt SK, et al. Multimodal microvascular imaging reveals that selective inhibition of class I PI3K is sufficient to induce an antivascular response. *Neoplasia*. 2013 Jul;15(7):694-711. PMID: 23814482.

Wallin JJ, Edgar KA, Guan J, et al. GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway. *Mol Cancer Ther*. 2011 Dec;10(12):2426-36. PMID: 21998291.

Caution: This product is intended for laboratory and research use only. It is not for human or drug use.